William Gradishar, MD, Northwestern Medicine

Articles by William Gradishar, MD, Northwestern Medicine

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 29th 2021

Adjuvant Systemic Therapy Data Updates

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 29th 2021

Adjuvant Systemic Therapy Decision Factors

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

Refining Treatment Approaches for HER2+ Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

January 20th 2021

A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.

William Gradishar, MD, Northwestern Medicine

Articles by William Gradishar, MD, Northwestern Medicine

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

Adjuvant Systemic Therapy Data Updates

Adjuvant Systemic Therapy Decision Factors

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

Refining Treatment Approaches for HER2+ Breast Cancer

Trending on OncLive

Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond

INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer

FDA Accepts NDA for Varegacestat in Desmoid Tumors

ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases

STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC